Dynavax jumps AH on HEPLISAV Phase 3 data


Shares of Dynavax (DVAX) jump 5.9% AH after the company announces the previously published results of 2 Phase 3 trials of its HEPLISAV hepatitis B vaccine.

Results from over 2,400 subjects aged 40-70 led the authors to conclude that the vaccine "induced significantly higher seroprotection rates in all groups (including hyporesponsive populations) than the licensed comparator hepatitis B vaccine ... while maintaining a similar safety profile."

The second trial in over 500 participants with chronic kidney disease determined that HEPLISAV provided "significantly higher seroprotection rates and earlier and more persistent seroprotection than the licensed conparator ... while maintaining a similar safety profile."

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs